Patents by Inventor Javier Fernando Chaparro Riggers

Javier Fernando Chaparro Riggers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12163169
    Abstract: The present invention provides inducible chimeric cytokine receptors responsive to a ligand, e.g., a small molecule or protein, uses of such receptors for improving the functional activities of genetically modified immune cells, such as T cells, comprising the inducible chimeric cytokine receptors, and compositions comprising such cells.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 10, 2024
    Assignee: Allogene Therapeutics, Inc.
    Inventors: Andrew Ross Nager, Spencer Park, Javier Fernando Chaparro Riggers, Regina Junhui Lin, Thomas John Van Blarcom
  • Patent number: 11912776
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: February 27, 2024
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • Patent number: 11814435
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: November 14, 2023
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
  • Patent number: 11702474
    Abstract: Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies. Also provided are uses of these antibodies, and related compositions and methods.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: July 18, 2023
    Assignee: Pfizer Inc.
    Inventors: Javier Fernando Chaparro Riggers, Shih-Hsun Chen, Sheng Ding, Pawel Kamil Dominik, Shahram Salek-Ardakani, Jessica Lynn Stanfield, Thomas John Van Blarcom
  • Publication number: 20220340671
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Application
    Filed: March 15, 2022
    Publication date: October 27, 2022
    Inventors: Tracy Chia-Chien KUO, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • Patent number: 11312782
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: April 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • Patent number: 11198735
    Abstract: The present invention provides antibodies that bind Glucocorticoid Induced Tumor necrosis factor Receptor family related protein (GITR) and methods of using same. The anti-GITR antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: December 14, 2021
    Assignee: Rinat Neuroscience Corp.
    Inventors: Samantha Lisa Bucktrout, Bevin Marie Brady Smith, Edward Derrick Pascua, Javier Fernando Chaparro Riggers
  • Patent number: 11155630
    Abstract: The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: October 26, 2021
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
  • Publication number: 20210324028
    Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
    Type: Application
    Filed: June 24, 2021
    Publication date: October 21, 2021
    Applicant: Pfizer Inc.
    Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
  • Patent number: 11059876
    Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: July 13, 2021
    Assignee: PFIZER INC.
    Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
  • Patent number: 10793635
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 6, 2020
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
  • Publication number: 20190263877
    Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
    Type: Application
    Filed: February 26, 2019
    Publication date: August 29, 2019
    Applicant: Pfizer Inc.
    Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
  • Patent number: 10294304
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 21, 2019
    Assignee: Pfizer Inc.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • Patent number: 10040860
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: August 7, 2018
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
  • Patent number: 9969809
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 15, 2018
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
  • Publication number: 20160311912
    Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.
    Type: Application
    Filed: December 21, 2015
    Publication date: October 27, 2016
    Inventors: Alison Jane Forgie, Javier Fernando Chaparro Riggers, Edward Roland Lavallie, Chia-Yang Lin, Lidia Mosyak, Andrea Rossi, Thomas John Van Blarcom
  • Patent number: 9248189
    Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: February 2, 2016
    Assignee: PFIZER INC.
    Inventors: Alison Jane Forgie, Javier Fernando Chaparro Riggers, Edward Roland Lavallie, Chia-Yang Lin, Lidia Mosyak, Andrea Rossi, Thomas John Van Blarcom
  • Patent number: 9249224
    Abstract: The present invention provides antagonizing antibodies that bind to growth hormone receptor (GHR). The invention further relates to therapeutic methods for use of these antibodies to reduce IGF-1 levels and/or for the treatment and/or prevention of diseases associated with excessive IGF-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis, and lung inflammation.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: February 2, 2016
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Sara Iva Siebel, Edward Derrick Pascua, Chia-Yang Lin, Javier Fernando Chaparro Riggers
  • Patent number: 9175093
    Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: November 3, 2015
    Assignees: RINAT NEUROSCIENCE CORP., PFIZER INC.
    Inventors: Hong Liang, Yasmina Noubia Abdiche, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Julie Jia Li Hawkins, Jaume Pons, Xiayang Qiu, Pavel Strop, Yuli Wang
  • Patent number: 9029515
    Abstract: The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: May 12, 2015
    Assignees: Rinat Neuroscience Corp., Pfizer Inc.
    Inventors: Jaume Pons, Jeffrey Raymond Chabot, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Hong Liang, Kapil Mayawala, Jerome Thomas Mettetal, II, Arvind Rajpal, David Louis Shelton